Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment

This study has been completed.
Sponsor:
Collaborator:
Capital Health, Canada
Information provided by:
University of Alberta
ClinicalTrials.gov Identifier:
NCT00351676
First received: July 12, 2006
Last updated: December 7, 2007
Last verified: February 2006
  Purpose

We, the researchers, propose to link a clinical pharmacist with an internal medicine or family medicine team to provide pharmaceutical care to all patients assigned to the team. The hypothesis is that through this team based approach, pharmacists will act as a resource for providing pharmacotherapeutic advice during the drug therapy decision making process and promote optimal drug use by identifying and resolving actual and potential drug related problems. This study is designed to test this hypothesis, by assessing the impact of this intervention on evidence based, quality of drug therapy indicators, for patients admitted with heart failure (HF), chronic obstructive pulmonary disease (COPD), community acquired pneumonia (CAP), type 2 diabetes mellitus (T2DM), and stable coronary artery disease (CAD).


Condition Intervention Phase
Heart Failure, Congestive
Pulmonary Disease, Chronic Obstructive
Pneumonia
Diabetes Mellitus, Type 2
Coronary Arteriosclerosis
Behavioral: Integration of a team based clinical pharmacist
Drug: Optimizing therapeutic treatments
Behavioral: Optimizing processes of care
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE)

Resource links provided by NLM:


Further study details as provided by University of Alberta:

Primary Outcome Measures:
  • Improvement in proportion of quality indicators achieved, for target diseases as a most responsible or primary diagnosis, between groups. [ Time Frame: in hospital ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Differences in condition-specific achievement of drug therapy quality indicators; [ Time Frame: in hospital ] [ Designated as safety issue: No ]
  • Differences in 6 month hospital readmission rate; [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Differences in number, type, acceptance rate, and expected impact of all pharmacist interventions; [ Time Frame: in hospital ] [ Designated as safety issue: No ]
  • Qualitative evaluation of the impact of the intervention via interviews with the participating pharmacists and physicians. [ Time Frame: in hospital ] [ Designated as safety issue: No ]

Enrollment: 452
Study Start Date: February 2006
Study Completion Date: July 2007
Detailed Description:

The overall goal of the COLLABORATE study is to improve processes of care and patient outcomes by optimizing drug therapy via a hospital pharmacy practice model that integrates clinical pharmacists into the patient care team.

The intervention consists of a clinical pharmacist assigned to the patient care team for the purpose of providing proactive clinical pharmacy services. The study pharmacist will be available during normal office hours 5 days per week to provide clarification of the patient's medication history, identify and resolve actual and potential patient specific drug related problems/issues, participate in patient care rounds, provide drug information to the patient care team, provide patient education and discharge medication counselling, and provide physician and/or nursing staff education. The anticipated pharmacist to patient ratio is approximately 1:20.

Control patients will receive usual care. Usual care consists of reactive clinical pharmacy services (i.e. drug related issues identified as orders are received, or by patient profile review) provided by a ward based, not team based, clinical pharmacist.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consecutive patients > 18 years of age admitted to participating internal and family medicine teams during the 1 year study period will be eligible to receive the pharmacist intervention. For the purposes of data analysis, patients with a most responsible or primary diagnosis of HF, COPD, CAP, T2DM, and CAD will be included.

Exclusion Criteria:

  • Residence outside the Capital Health catchment
  • Admitted for ≤ 2 days
  • Palliative care
  • Transferred to another team
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00351676

Locations
Canada, Alberta
Grey Nuns Community Hospital
Edmonton, Alberta, Canada, T6L 5X8
Royal Alexandra Hospital
Edmonton, Alberta, Canada, T5H 3V9
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Sponsors and Collaborators
University of Alberta
Capital Health, Canada
Investigators
Principal Investigator: Ross T. Tsuyuki, PharmD, MSc University of Alberta
  More Information

Additional Information:
No publications provided by University of Alberta

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Ross Tsuyuki, University of Alberta
ClinicalTrials.gov Identifier: NCT00351676     History of Changes
Other Study ID Numbers: EPICORE-2006-001
Study First Received: July 12, 2006
Last Updated: December 7, 2007
Health Authority: Canada: Ethics Review Committee

Keywords provided by University of Alberta:
Drug Therapy
Hospitals, Teaching
Hospitals, Community
Interprofessional relations
Patient Care Team
Pharmacists
Pharmacy Service, Hospital
Comparative Study
Hospitalization

Additional relevant MeSH terms:
Arteriosclerosis
Atherosclerosis
Chronic Disease
Coronary Artery Disease
Diabetes Mellitus
Diabetes Mellitus, Type 2
Heart Failure
Lung Diseases
Myocardial Ischemia
Pulmonary Disease, Chronic Obstructive
Arterial Occlusive Diseases
Cardiovascular Diseases
Coronary Disease
Disease Attributes
Endocrine System Diseases
Glucose Metabolism Disorders
Heart Diseases
Lung Diseases, Obstructive
Metabolic Diseases
Pathologic Processes
Respiratory Tract Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014